Affordable Access

deepdyve-link
Publisher Website

Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents.

Authors
  • Tsatsos, Michael1, 2, 3, 4
  • MacGregor, Cheryl2
  • Athanasiadis, Ioannis3
  • Moschos, Marilita M4
  • Hossain, Parwez2
  • Anderson, David2
  • 1 Royal Eye Infirmary, Dorset County Hospital NHS Foundation Trust, Dorchester, UK.
  • 2 Southampton University Hospitals NHS Foundation Trust, Southampton, UK.
  • 3 Moorfields Eye Hospital NHS Foundation Trust, London, UK.
  • 4 University of Athens, Athens, Greece.
Type
Published Article
Journal
Clinical & experimental ophthalmology
Publication Date
December 2016
Volume
44
Issue
9
Pages
824–837
Identifiers
DOI: 10.1111/ceo.12785
PMID: 27273328
Source
Medline
Keywords
License
Unknown

Abstract

Ophthalmic herpes simplex viral keratitis is responsible for a range of ocular manifestations from superficial epithelial disease to stromal keratitis and endotheliitis. The Herpetic Eye Disease Study has guided the management of herpetic eye disease for almost twenty years, but newer medications such as valacyclovir are now available and are considered to have better bioavailability than acyclovir. In this review, we examine the existing evidence on the pathogenesis of different ophthalmic herpes simplex viral keratitis disease modalities and the role of oral and topically administered antiviral drugs in the treatment of herpes simplex viral keratitis.

Report this publication

Statistics

Seen <100 times